ILD Clinical Trials and Research Roles for APPs

As new therapies and diagnostic innovations are introduced, the management of interstitial lung Disease continues to change, elevating the importance of ILD Clinical Trials and Research Roles for APPs. Clinical research, in particular, is critical to establishing new standards of care for idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF), connective tissue disease-associated ILD (CTD-ILD), hypersensitivity pneumonitis, and other fibrotic lung diseases.

ILD clinical trials and research roles for APPs consist of recognizing, screening, and enrolling patients, educating patients about investigational research, and monitoring the safety and adherence to the protocol while participating in and contributing to interdisciplinary research. Advanced practice providers (APPs) are critical in facilitating communication among the patients, the investigators, and the research team. Through expert discussions, structured educational initiatives, and collaborative tools on the ILD Community Network, APPs can initiate and expand their role in ILD clinical research and innovation.

The ILD clinical trials and research roles for APPs demonstrate the importance advanced practice providers have in roles such as patient identification, trial coordination, safety monitoring, and multifaceted research collaboration. As APPs work on research, it aids ILD providers in prioritizing patient-centered care while also increasing the care options available as range of treatments for ILD continues to progress.

APPs are also able to advance their involvement in ILD clinical research and innovation through clinical updates, digital education, and professional networking via the ILD Community Network.

#ildclinicaltrials #ildresearchroles #apps #advancedpracticeproviders #ild